Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial.
about
Bevacizumab with metronomic chemotherapy of low-dose oral cyclophosphamide in recurrent cervical cancer: Four cases.Major clinical research advances in gynecologic cancer in 2017.Tumor molecular profiling of responders and non-responders following pembrolizumab monotherapy in chemotherapy resistant advanced cervical cancer.Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitorsGene Expression Analysis Identifies Novel Targets for Cervical Cancer Therapy
P2860
Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Safety and Efficacy of Pembrol ...... he Phase Ib KEYNOTE-028 Trial.
@en
Safety and Efficacy of Pembrol ...... he Phase Ib KEYNOTE-028 Trial.
@nl
type
label
Safety and Efficacy of Pembrol ...... he Phase Ib KEYNOTE-028 Trial.
@en
Safety and Efficacy of Pembrol ...... he Phase Ib KEYNOTE-028 Trial.
@nl
prefLabel
Safety and Efficacy of Pembrol ...... he Phase Ib KEYNOTE-028 Trial.
@en
Safety and Efficacy of Pembrol ...... he Phase Ib KEYNOTE-028 Trial.
@nl
P2093
P356
P1476
Safety and Efficacy of Pembrol ...... the Phase Ib KEYNOTE-028 Trial
@en
P2093
Andrea Varga
Bert O'Neil
Carlos Gomez-Roca
Christophe Le Tourneau
Emilie M J van Brummelen
Hope S Rugo
Patrick A Ott
Reshma Rangwala
Sanatan Saraf
Shari Thomas
P304
P356
10.1200/JCO.2017.74.5471
P407
P577
2017-11-02T00:00:00Z